MA30085B1 - Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione - Google Patents

Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione

Info

Publication number
MA30085B1
MA30085B1 MA31071A MA31071A MA30085B1 MA 30085 B1 MA30085 B1 MA 30085B1 MA 31071 A MA31071 A MA 31071A MA 31071 A MA31071 A MA 31071A MA 30085 B1 MA30085 B1 MA 30085B1
Authority
MA
Morocco
Prior art keywords
thiazolidinedione
metformin
diabetes
treatment
type
Prior art date
Application number
MA31071A
Other languages
English (en)
Inventor
Jonathan Rachman
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35841111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30085(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of MA30085B1 publication Critical patent/MA30085B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Traitement du diabète de type 2 avec une association d'un inhibiteur de DPIV et de metformine ou d'une thiazolidinedione La présente invention concerne une méthode thérapeutique pour la régulation de la glycémie, en particulier une méthode pour le traitement du diabète de type 2, comprenant l'administration d'un inhibiteur de DPIV conjointement avec de la metformine ou une thiazolidinedione.
MA31071A 2005-12-23 2008-06-23 Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione MA30085B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0526291.0A GB0526291D0 (en) 2005-12-23 2005-12-23 Therapeutic method

Publications (1)

Publication Number Publication Date
MA30085B1 true MA30085B1 (fr) 2008-12-01

Family

ID=35841111

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31071A MA30085B1 (fr) 2005-12-23 2008-06-23 Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione

Country Status (27)

Country Link
US (3) US20100216800A1 (fr)
EP (1) EP1965783B1 (fr)
JP (2) JP2009520801A (fr)
KR (1) KR20080080220A (fr)
CN (1) CN101365434A (fr)
AU (1) AU2006327974B2 (fr)
BR (1) BRPI0620450A2 (fr)
CA (1) CA2634379C (fr)
CY (1) CY1114401T1 (fr)
DK (1) DK1965783T3 (fr)
EA (1) EA017084B1 (fr)
ES (1) ES2427822T3 (fr)
GB (1) GB0526291D0 (fr)
HR (1) HRP20130880T1 (fr)
IL (1) IL192257A0 (fr)
MA (1) MA30085B1 (fr)
MX (1) MX2008008250A (fr)
NO (1) NO20082790L (fr)
NZ (1) NZ569427A (fr)
PL (1) PL1965783T3 (fr)
PT (1) PT1965783E (fr)
RS (1) RS52942B (fr)
SG (1) SG186610A1 (fr)
SI (1) SI1965783T1 (fr)
UA (1) UA100111C2 (fr)
WO (1) WO2007072083A1 (fr)
ZA (1) ZA200806200B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
UA98799C2 (ru) 2007-07-19 2012-06-25 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP5713990B2 (ja) * 2010-03-08 2015-05-07 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ２型糖尿病治療用の医薬組成物
WO2011138421A1 (fr) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combinaison thérapeutique
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
CA2841552C (fr) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Quinazolines substituees, la preparation de celles-ci et l'utilisation de celles-ci dans des compositions pharmaceutiques
MX2014008190A (es) 2012-01-06 2015-02-04 Elcelyx Therapeutics Inc Composiciones de biguanida y métodos para tratar transtornos metabólicos.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9096541B2 (en) 2012-03-29 2015-08-04 Oklahoma Medical Research Foundation Inhibition of memapsin 1 cleavage in the treatment of diabetes
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (fr) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (fr) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinaisons de linagliptine et de metformine
EP3958857A1 (fr) 2019-09-17 2022-03-02 Novartis AG Multithérapie comprenant de la vildagliptine et de la metformine
US20220160619A1 (en) * 2020-11-25 2022-05-26 Complete Medical Solutions, Llc Effervescent Drug Formulations

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
WO1998018763A1 (fr) 1996-10-25 1998-05-07 Tanabe Seiyaku Co., Ltd. Derives de tetrahydroisoquinoline
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
WO1999025719A1 (fr) 1997-11-18 1999-05-27 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Substance physiologiquement active, la sulphostine, procede de fabrication et utilisation
EP2823812A1 (fr) 1998-02-02 2015-01-14 Trustees Of Tufts College Inhibiteurs de dipeptidylpeptidase-IV pour leur utilisation dans le traitement du diabète de type II
EP1062222A1 (fr) 1998-03-09 2000-12-27 Fondatech Benelux N.V. Modulateurs de la serine peptidase
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
WO1999062914A1 (fr) 1998-06-05 1999-12-09 Point Therapeutics, Inc. Composes cycliques de boroproline
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
WO2000053171A1 (fr) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Utilisation de metformine dans la preparation de compositions pharmaceutiques pouvant inhiber l'enzyme dipeptidyl peptidase iv
AU1916401A (en) 1999-11-12 2001-06-06 Guilford Pharmaceuticals Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
DK1248604T4 (da) 2000-01-21 2012-05-21 Novartis Ag Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
AU2001228309A1 (en) 2000-01-24 2001-08-07 Novo-Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001254763A1 (en) 2000-03-31 2001-10-08 Prosidion Limited Method for the improvement of islet signaling in diabetes mellitus and for its prevention
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
AU6895801A (en) 2000-07-04 2002-01-14 Novo Nordisk As Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
AU2001278988A1 (en) 2000-07-21 2002-02-05 John F. Corcoran Intermodal container pallet
DK1308439T3 (da) 2000-08-10 2009-01-12 Mitsubishi Tanabe Pharma Corp Prolinderivater og anvendelse af disse som lægemidler
ATE407924T1 (de) 2000-10-06 2008-09-15 Mitsubishi Tanabe Pharma Corp Stickstoffhaltige, fünfgliedrige ringverbindungen
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002053548A1 (fr) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Derives de la benzothiazepine
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
PE20021002A1 (es) 2001-02-02 2002-12-06 Takeda Chemical Industries Ltd Compuestos heterociclicos condensados
WO2002066627A1 (fr) 2001-02-16 2002-08-29 Bayer Aktiengesellschaft Regulation de la dipeptidyle peptidase 8 humaine
EE05643B1 (et) 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
WO2002067918A1 (fr) 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Nouveau derive de diallylmethylamine
JP2002265439A (ja) 2001-03-08 2002-09-18 Mitsubishi Pharma Corp シアノピロリジン誘導体およびその医薬用途
EP1385508B1 (fr) 2001-03-27 2008-05-21 Merck & Co., Inc. Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete
FR2822826B1 (fr) 2001-03-28 2003-05-09 Servier Lab Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0109146D0 (en) 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE523510C2 (sv) 2001-05-18 2004-04-27 Jan G Faeger Förfarande för att fastställa en varelses position och/eller orientering i förhållande till en omgivning
US20030060494A1 (en) 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
DE60209348T2 (de) 2001-06-20 2006-10-12 Merck & Co., Inc. Dipeptidylpeptidase-hemmer zur behandlung von diabetes
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
WO2003002530A2 (fr) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase
US20030005443A1 (en) 2001-06-27 2003-01-02 Karin Axelsson EPG having PIP window history and sample view functionality
ATE385238T1 (de) 2001-06-27 2008-02-15 Probiodrug Ag Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
CN1723196A (zh) 2001-06-27 2006-01-18 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
ATE370943T1 (de) 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
WO2003003250A1 (fr) 2001-06-28 2003-01-09 Hywire Ltd. Memoire adressable par son contenu constituee de plages
EP1404675B1 (fr) 2001-07-03 2008-03-12 Novo Nordisk A/S Derives de purine inhibiteurs de dpp-iv pour le traitement du diabete
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
EP1463727A2 (fr) 2001-09-19 2004-10-06 Novo Nordisk A/S Composes heterocycliques constituant des inhibiteurs de l'enzyme dpp-iv
KR20040054729A (ko) 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
AU2002360732A1 (en) 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
WO2003057200A2 (fr) 2002-01-11 2003-07-17 Novo Nordisk A/S Methode et composition permettant de traiter le diabete, l'hypertension, l'insuffisance cardiaque chronique et les troubles de retention de fluide
CN1308311C (zh) 2002-02-13 2007-04-04 霍夫曼-拉罗奇有限公司 新型吡啶－和喹啉－衍生物
ATE472536T1 (de) 2002-02-13 2010-07-15 Hoffmann La Roche Pyridin- und pyrimidin-derivate
EP1338595B1 (fr) 2002-02-25 2006-05-03 Eisai Co., Ltd. Dérivés de Xanthines servant d'inhibiteurs de DPP-IV
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
KR20040105853A (ko) 2002-04-08 2004-12-16 토렌트 파마슈티칼스 리미티드 티아졸리딘-4-카르보니트릴 및 유사체와디펩티딜-펩티다아제 억제제로서의 용도
JP2003300977A (ja) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd キサンチン誘導体
CA2484551A1 (fr) 2002-04-30 2003-11-13 Trustees Of Tufts College Inhibiteurs de protease
MXPA04011958A (es) 2002-06-04 2005-03-31 Pfizer Prod Inc Amidas ciclicas fluoradas como inhibidores de la dipeptidil peptidasa iv.
AU2003233010A1 (en) 2002-06-04 2003-12-19 Pfizer Products Inc. Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
US20060100199A1 (en) 2002-06-06 2006-05-11 Seiji Yoshikawa Novel condensed imidazole derivatives
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
WO2004016840A1 (fr) 2002-08-13 2004-02-26 Kanebo, Ltd. Produit fonctionnel, poudre fine fonctionnelle utilisable lors de la production d'un tel produit, procede de production d'un produit fonctionnel
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
CN102964347B (zh) 2002-08-21 2015-11-18 勃林格殷格翰制药两合公司 8-[3-氨基-哌啶-1-基]-黄嘌呤化合物，其制备方法及作为药物制剂的用途
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
WO2004024184A1 (fr) 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited Preparation a liberation prolongee
AU2003282800B2 (en) 2002-09-19 2009-10-29 Abbvie Inc. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
AU2003269850A1 (en) 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
DK1556362T3 (da) 2002-10-18 2008-06-09 Merck & Co Inc Heterocykliske beta-aminodipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
ATE469645T1 (de) 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
AU2003286776A1 (en) 2002-10-30 2004-06-07 Guilford Pharmaceuticals Inc. Novel inhibitors of dipeptidyl peptidase iv
MXPA05004890A (es) 2002-11-07 2005-07-22 Merck & Co Inc Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes.
AU2003274601A1 (en) 2002-11-18 2004-06-15 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
AU2002952946A0 (en) 2002-11-27 2002-12-12 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
AU2003297564A1 (en) 2002-12-04 2004-06-23 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
ATE447574T1 (de) 2003-05-14 2009-11-15 Merck & Co Inc 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
AU2004249163A1 (en) 2003-06-17 2004-12-29 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
PE20050249A1 (es) 2003-07-25 2005-06-01 Aventis Pharma Gmbh Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
DE10333935A1 (de) 2003-07-25 2005-02-24 Aventis Pharma Deutschland Gmbh Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20060054371A (ko) 2003-07-31 2006-05-22 쓰리엠 이노베이티브 프로퍼티즈 컴파니 캡슐화 및 제어된 방출을 위한 조성물
US20050026881A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
WO2005019168A2 (fr) 2003-08-20 2005-03-03 Pfizer Products Inc. Derives fluores de lysine en tant qu'inhibiteurs de la dipeptidylpeptidase iv
US20060287251A1 (en) * 2003-09-02 2006-12-21 Hans-Ulrich Demuth Combination therapy for glycaemic control
WO2005030751A2 (fr) 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyle peptidase
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
AR046330A1 (es) 2003-09-09 2005-12-07 Japan Tobacco Inc Inhibidor de dipeptidilpeptidasa iv
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
TW200519105A (en) 2003-10-20 2005-06-16 Lg Life Science Ltd Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
WO2005044195A2 (fr) 2003-11-04 2005-05-19 Merck & Co., Inc. Derives de phenylalanine fusionnes utilises comme inhibiteurs de la dipeptidyl peptidase-iv dans le traitement ou la prevention du diabete
EP1689757B1 (fr) 2003-11-12 2014-08-27 Phenomix Corporation Composes heterocycliques d'acide boronique
US20070105890A1 (en) 2003-11-26 2007-05-10 Dainippon Sumitomo Pharma Co., Ltd Novel condensed imidazole derivative
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1541148A1 (fr) 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Inhibiteurs de dpp-iv
EP1541143A1 (fr) 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Inhibiteurs de dpp-iv
CN1890228B (zh) 2003-12-11 2011-07-20 田边三菱制药株式会社 α-氨基酸衍生物及其作为药物的应用
WO2005058849A1 (fr) 2003-12-15 2005-06-30 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procede de preparation et compositions les contenant
DE10359098A1 (de) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
WO2005073186A1 (fr) 2004-01-29 2005-08-11 Ono Pharmaceutical Co., Ltd. Dérivés de pyrrolidine
WO2005075426A1 (fr) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procedes de preparation et compositions en comportant
ATE537141T1 (de) 2004-02-05 2011-12-15 Kyorin Seiyaku Kk Bicycloesterderivat
CA2555050C (fr) 2004-02-18 2017-11-28 Boehringer Ingelheim International Gmbh Derives de 8-[3-amino-piperidine-1-yl]-xanthines, la production de ceux-ci et leur utilisation sous la forme d'un inhibiteur de dpp-iv
WO2005077900A1 (fr) 2004-02-18 2005-08-25 Kyorin Pharmaceutical Co., Ltd. Dérivés d'amides bicycliques
KR101292707B1 (ko) 2004-02-23 2013-08-02 트러스티즈 오브 터프츠 칼리지 디펩티딜펩티다아제 ⅳ의 억제제
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
EP1719757B1 (fr) 2004-02-27 2013-10-09 Kyorin Pharmaceutical Co., Ltd. Derive bicyclo
KR100552043B1 (ko) 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
EP1593671A1 (fr) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG Inhibiteurs de la DPP-IV
EP1729774A4 (fr) 2004-03-09 2009-05-06 Nat Health Research Institutes Composes de pyrrolidine
DE102004012366A1 (de) 2004-03-13 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Imidazopyridazindione, deren Herstellung und deren Verwendung als Arzneimittel
EA013427B1 (ru) 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
WO2005095339A1 (fr) 2004-03-31 2005-10-13 Pfizer Products Inc. Dicyanopyrrolidines inhibiteurs de la dipeptidyl peptidase iv
JP2007531780A (ja) 2004-04-10 2007-11-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な２−アミノ−イミダゾ［４，５−ｄ］ピリダジン−４−オン及び２−アミノ−イミダゾ［４，５−ｃ］ピリダジン−４−オン、その製法及び医薬としての使用
WO2005100334A1 (fr) 2004-04-14 2005-10-27 Pfizer Products Inc. Inhibiteurs de dipeptidyl peptidase-iv
TW200604167A (en) 2004-04-27 2006-02-01 Astellas Pharma Inc Pyrrolidine derivatives
CA2564264A1 (fr) 2004-05-04 2005-11-17 Merck & Co., Inc. Derives de 1,2,4-oxadiazole en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le traitement ou la prevention de diabetes
EP1598341A1 (fr) 2004-05-21 2005-11-23 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft Inhibiteurs de DPP-IV
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
JP2008501714A (ja) 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
EP1604662A1 (fr) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft Derivés de la benzyl amine du acide carboxylique (2R) de la 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine et composés similaires pour l'utilisation comme inhibiteurs de la peptidase dipeptidyl IV (DPP-IV) pour le traitement de la diabetes mellitus de type 2

Also Published As

Publication number Publication date
KR20080080220A (ko) 2008-09-02
AU2006327974A1 (en) 2007-06-28
IL192257A0 (en) 2009-02-11
JP2013227337A (ja) 2013-11-07
RS52942B (sr) 2014-02-28
NO20082790L (no) 2008-09-16
NZ569427A (en) 2011-11-25
PL1965783T3 (pl) 2013-11-29
EP1965783A1 (fr) 2008-09-10
US20140051734A1 (en) 2014-02-20
ZA200806200B (en) 2009-04-29
CN101365434A (zh) 2009-02-11
JP2009520801A (ja) 2009-05-28
HRP20130880T1 (hr) 2013-10-25
UA100111C2 (ru) 2012-11-26
EA017084B1 (ru) 2012-09-28
US20100216800A1 (en) 2010-08-26
CA2634379A1 (fr) 2007-06-28
US20160279105A1 (en) 2016-09-29
AU2006327974B2 (en) 2012-10-04
DK1965783T3 (da) 2013-08-05
BRPI0620450A2 (pt) 2011-11-08
HK1121074A1 (en) 2009-04-17
EA200801538A1 (ru) 2008-12-30
WO2007072083A1 (fr) 2007-06-28
CA2634379C (fr) 2014-05-20
CY1114401T1 (el) 2016-08-31
GB0526291D0 (en) 2006-02-01
SG186610A1 (en) 2013-01-30
MX2008008250A (es) 2008-11-06
SI1965783T1 (sl) 2013-10-30
ES2427822T3 (es) 2013-11-04
EP1965783B1 (fr) 2013-06-19
PT1965783E (pt) 2013-08-27

Similar Documents

Publication Publication Date Title
EA200801538A1 (ru) Лечение диабета 2 типа комбинацией ингибитора дипептидилпептидазы iv (dpiv) и метформина или тиазолидиндиона
BRPI0416628A (pt) uso de compostos orgánicos
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA29387B1 (fr) Inhibiteurs de la dipeptidyl peptidase iv
MA27548A1 (fr) Inhibiteurs heterocycliques beta-amines de la dipeptidyl peptidase pour le traitement ou la prevention du diabete.
GB0318447D0 (en) Therapeutic agents
MA30632B1 (fr) Anticorps humanisé
EP1490335A4 (fr) Inhibiteurs de la dipeptidyl peptidase beta-amino heterocycliques pour le traitement ou la prevention du diabete
EP1385508A4 (fr) Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete
EP1406872A4 (fr) Inhibiteurs de dipeptidyle peptidase pour le traitement du diabete
MA29836B1 (fr) Proteines de fusion avec l'albumine
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
JP2007534657A5 (fr)
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
MY141972A (en) Biaryloxymethylarenecarboxylic acids
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren